xml version="1.0" encoding="utf-8" ?   8-K    

   METLIFE INC false 0001099219 --12-31        0001099219   2020-01-07 2020-01-07     0001099219  us-gaap:CommonStockMember    2020-01-07 2020-01-07     0001099219  us-gaap:SeriesAPreferredStockMember    2020-01-07 2020-01-07     0001099219  us-gaap:SeriesEPreferredStockMember    2020-01-07 2020-01-07      

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, DC 20549 

FORM 8-K 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) 

OF THE SECURITIES EXCHANGE ACT OF 1934 

Date of report (Date of earliest event reported): January 7, 2020 

 METLIFE, INC.  

(Exact Name of Registrant as Specified in Its Charter) 

  [DATA_TABLE_REMOVED] [DATA_TABLE_REMOVED] 

212-578-9500 

(Registrant’s Telephone Number, Including Area Code) 

N/A 

(Former Name or Former Address, if Changed Since Last Report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

  ☐  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

  ☐  

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

  ☐  

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

  ☐  

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 Item 3.03  

Material Modification to Rights of Security Holders   

Upon issuance of the 4.75% Non-Cumulative Preferred Stock, Series F, par value $0.01 per share and liquidation preference $25,000 per share (the “Preferred Stock”) by MetLife, Inc. expected to take place on January 15, 2020, the ability of MetLife, Inc. to declare or pay dividends on, or purchase, redeem or otherwise acquire, shares of its common stock or any shares of MetLife, Inc. that rank junior to, or on parity with, the Preferred Stock will be subject to certain restrictions in the event that MetLife, Inc. does not declare and pay (or set aside) dividends on the Preferred Stock for the last preceding dividend period. The terms of the Preferred Stock, including such restrictions, are more fully described in the Certificate of Designations for the Preferred Stock, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein by reference.  

 Item 5.03  

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year   

On January 8, 2020, MetLife, Inc. filed a Certificate of Designations with the Secretary of State of the State of Delaware to establish the preferences, limitations and relative rights of the Preferred Stock. The Certificate of Designations became effective upon filing, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein by reference.  

 Item 8.01  

Other Events   

On January 7, 2020, MetLife, Inc. entered into (i) an Underwriting Agreement (the “Underwriting Agreement”) and (ii) a Pricing Agreement (the “Pricing Agreement”) with Wells Fargo Securities, LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, UBS Securities LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named in Schedule I to the Pricing Agreement (the “Underwriters”), with respect to the offer and sale by MetLife, Inc. of an aggregate of 40,000,000 depositary shares (the “Depositary Shares”), each representing a 1/1,000th interest in a share of the Preferred Stock. The offering and sale of the Depositary Shares and Preferred Stock were registered under MetLife, Inc.’s registration statement on Form S-3 (File No. 333-234761), and a prospectus supplement related to the Depositary Shares dated January 7, 2020 (filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended).  

The Underwriting Agreement and the Pricing Agreement are being filed with this Current Report on Form 8-K as Exhibit 1.1 and Exhibit 1.2 hereto, respectively, and are incorporated herein by reference.  

 Item 9.01  

Financial Statements and Exhibits.   [DATA_TABLE_REMOVED] 

SIGNATURE  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  [DATA_TABLE_REMOVED]